Gary W. Jay, MD is currently Clinical Professor, Dept. of Neurology, Division: Headache/Pain at UNC, Chapel Hill, NC. He previously owned and ran an interdisciplinary Pain, Headache and mTBI NeuroRehabilitation Center for 26 years. He was a founder of the American Academy of Pain Medicine and the American Academy of Pain Management. He has been President of National, Regional and State Pain Medicine Groups. He then went into Pharma, became Chief Medical Officer of 2 Pharmas and a CRO. Dr. Jay then returned to Medicine at UNC. He has published 5 textbooks and over 170 peer reviewed journal articles and textbook chapters. He was also a part of the IMMPACT group while in Pharma. He continues to speak nationally on various topics (Pain, Headache and mTBI) and the issues dealing with the “opioid crisis” and the unanticipated or purposeful patient problems with this.
Steven D. Passik, Ph.D. Vice President, Scientific Affairs, Education, and Policy, COLLEGIUM PHARMACEUTICALS
After a 25-year academic and clinical career at Memorial Sloan Kettering Cancer Center, University of Kentucky and Vanderbilt University, Dr. Passik spent the past five and one-half years in the toxicology and most recently the pharmaceutical industry. He is presently the Vice President of Scientific Affairs, Education and Policy at Collegium Pharmaceuticals. His research has focused on the interface of pain management and addiction and psychiatric aspects of cancer and non-cancer pain and symptom management. He has served as editor and reviewer for multiple journals in pain and psycho-oncology. He has authored over 200 scholarly publications.
Tim Peara President and Finance Director, BRIDGE THERAPEUTICS
Joseph V. Pergolizzi, M.D. Senior Partner, NAPLES ANESTHESIA AND PAIN ASSOCIATES
Robert Raffa, Ph.D. Chief Scientific Officer, NEUMENTUM, INC.
Sebastian Schwier International Technical Project Leader, GRUNENTHAL
Sebastian Schwier, Ph.D., is Project Director within the Innovation Unit Devices and Technologies at Grunenthal GmbH in Aachen, Germany. He is responsible for leading CMC development teams including projects with Grunenthal’s INTAC® technology. Further, he is driving transfer activities and is part of the Category One Focus group for abuse-deterrent formulations.
Dr. Schwier joined Grunenthal’s corporate headquarters in Aachen, Germany in 2008 as a laboratory head in the Pharmaceutical Development department developing abuse-deterrent formulations (ADFs). Since 2012 he is responsible as CMC project leader for the development of ADFs internally as well as in collaboration with partners. In addition, he steers collaborations with partners on developing, manufacturing and testing ADFs.
Dr. Schwier received his degree as Pharmacist and later achieved a Ph.D. in Pharmaceutical Technology and Biopharmaceutics from the University of Munster, Germany.
Joe Stauffer Chief Medical Officer, INHERIS BIOPHARMA
Alex Wasyl Chief Executive Officer, NEXIEN BIOPHARMA
Debra R. Wilson, Ph.D. Contributing Faculty, WALDEN UNIVERSITY & AUSTIN PEAY STATE UNIVERSITY
John A. Zebala M.D., Ph.D. Chief Executive Officer and President, SYNTRIX PHARMACEUTICALS